Unsubscribe

A message from Market Jar, Inc

Hey there,

Every generation of markets rewards one kind of infrastructure.

The 1990s belonged to the internet.
The 2010s belonged to cloud computing.
The 2020s belong to real-time finance.

A brand-new US ETF just listed to capture that transformation. It tracks a payment rail that settles value in 3 to 5 seconds, with consistent, transparent fees.

You don't need a wallet or a crypto exchange. You simply trade a ticker.

Institutional custody and administration keep the structure familiar. The single-asset focus and 0.50% fee keep it clean.*

It's the opposite of hype: a tool built for function.

When similar funds launched, investors poured in. Bitwise's Solana product opened strong with roughly $55 million on day one, nine-figure assets in weeks. Those flows showed Wall Street wants digital exposure that fits compliance, not chaos.

Now that same model targets the payments lane, the one used daily by fintechs, treasuries, and cross-border networks.

If you think money should move as fast as data, this ETF is the most direct way to hold that view.

See the name and symbol now.

*Brokerage commissions apply and will reduce returns

For standardized returns of the Canary XRP ETF, please visit [XRP ETF - Canary Capital. Past performance does not guarantee future results.

The Fund's investment objectives, risks, charges and expenses should be considered before investing. The prospectus contains this and other important information, and it may be obtained at https://etfs.canary.capital/XRPC/prospectus/. Read it carefully before investing.

The Fund is not an investment company registered under the Investment Company Act of 1940 (the "1940 Act"), and therefore is not subject to the same regulatory requirements as mutual funds or traditional ETFs registered under the 1940 Act.

Investing Involves Significant Risk. The loss of principal is possible. Canary XRP ETF (the "Fund") may not be suitable for all investors. This document does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial advisor/financial consultant before making any investment decisions.

The fund is new with a limited operating history.

Digital assets, such as XRP, are a relatively new asset class, and the market for digital assets is subject to rapid changes and uncertainty. Digital assets are largely unregulated and digital asset investments may be more susceptible to fraud and manipulation than more regulated investments.

XRP is subject to unique and substantial risks, including significant price volatility and lack of liquidity, and theft. The value of an investment in the Fund could decline significantly and without warning, including to zero. XRP is subject to rapid price swings, including as a result of actions and statements by influencers and the media, changes in the supply of and demand for digital assets, and other factors. There is no assurance that XRP will maintain its value over the long-term. The Fund is not actively managed and will not take any actions to take advantage, or mitigate the impacts, of volatility in the price of XRP. An investment in the Fund is not a direct investment in XRP. Investors will not have any rights that XRP holders have and will not have the right to receive any redemption proceeds in XRP. Shares of the Fund are generally bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Only Authorized Participants may trade directly with the Fund and only large blocks of Shares called "creation units." Your brokerage commissions will reduce returns.

Paralel Distributors LLC serves as the marketing agent. Paralel is unaffiliated with Canary Capital and Native Ads.

Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Today's editorial pick for you

4 Healthcare Stocks to Buy in a Rotation Trade

Posted On Nov 19, 2025 by Chris Markoch

Investors who have ridden the technology rally over the past two years may be wondering if it's time to take profits and rebalance. The next phase of market leadership could come from sectors offering stability and dependable earnings power. Healthcare stocks stand out as that natural next step. These stocks offer a blend of defensive qualities, consistent cash flows, and innovation pipelines.

The healthcare sector’s diversity also helps spread risk across different economic environments.

Insurers and distributors benefit from long-term demographic trends
MedTech firms are positioned for procedure growth and robotic innovation.
Biopharma companies combine steady cash flow from established drugs with optionality from new therapies.

Healthcare stocks aren’t necessarily cheap across the board, but relative to the technology sector, these stocks have a refreshing valuation. For investors seeking balance, here are four healthcare stocks offering varying flavors of quality exposure.

Healthcare Stocks #1: Reliable Cash Flow and Defensive Value

Cardinal Health (NYSE: CAH) offers investors pure exposure to the backbone of the U.S. healthcare supply chain. As a distributor of medical and pharmaceutical products, it's a volume-driven business that benefits from rising healthcare consumption rather than breakthrough discoveries.

Recent cost efficiency improvements and share buybacks have lifted sentiment after years of margin pressure. Its consistent cash generation and modest valuation provide a safe harbor for those seeking defensiveness amid broader market volatility. With a forward P/E around 26x and improving profitability, Cardinal Health represents value-oriented exposure to a critical healthcare service.

Healthcare Stocks #2: Innovation-Driven Growth in Medical Devices

Medtronic (NYSE: MDT) remains one of the best-positioned medtech companies for a post-pandemic rebound in surgical procedures. With reopening tailwinds normalizing, its cardiac and diabetes units are regaining growth momentum. The company's focus on surgical robotics, particularly its Hugo robotic-assisted surgery platform, could serve as a key catalyst for longer-term innovation-driven upside.

While the stock has lagged peers due to execution concerns, its yield and consistent R&D investment support a patient investor thesis. For those seeking a mix of income and exposure to technology-driven healthcare devices, Medtronic offers that middle ground.

Healthcare Stocks #3: Pipeline Strength and High-Yield Pharma

AbbVie Inc. (NYSE: ABBV) sits at an interesting inflection point. The company has managed the loss of exclusivity for its blockbuster drug Humira better than many expected, thanks to strong performance from Skyrizi and Rinvoq. These newer immunology therapies have already replaced much of Humira's revenue base and position AbbVie as a durable cash-flow generator.

The company trades at a modest valuation compared to the broader market and offers a yield north of 3 percent, making it appealing for value-oriented investors looking for income and steady earnings. Its consistent dividend growth underscores AbbVie's reputation as a reliable blue-chip pharma holding.

Healthcare Stocks #4: Breakthrough Growth With GLP-1 Leadership

Eli Lilly & Co. (NYSE: LLY) has been the market's darling in the healthcare sector, and for good reason. Its leadership in the GLP-1 weight-loss and diabetes category has reshaped the company's earnings trajectory. With drugs like Mounjaro and Zepbound fueled by global demand, Lilly is posting breakout revenue growth alongside expanding margins.

While its valuation is rich, growth expectations justify much of the premium, especially given the long runway in obesity treatment markets. Beyond GLP-1 therapy, Lilly's Alzheimer's drug pipeline offers additional optionality. For investors willing to pay a premium for innovation, Lilly remains the quintessential healthcare growth stock.

What Could Go Wrong with the Thesis?

The main risk to this healthcare rotation thesis lies in timing and market psychology. If technology stocks continue outperforming—driven by AI enthusiasm or easing rate expectations—capital may remain concentrated in growth sectors. Additionally, healthcare's regulatory backdrop always carries uncertainty; pricing reforms or reimbursement changes could compress margins across the industry.

Company-specific execution risks, such as Medtronic's product launches or AbbVie's pipeline transitions, should also be monitored. In short, while healthcare offers balance, it is not immune to macro or policy shocks.

Conclusion

As investors seek stability after an extended tech-led bull run, healthcare provides a refreshing mix of defensiveness, yield, and innovation. Cardinal Health delivers steady value, Medtronic offers device-driven recovery potential, AbbVie anchors with reliable cash flow and dividends, and Eli Lilly supplies pure growth leadership. Together, they form a diversified healthcare basket well-suited for investors navigating a maturing market cycle..

This message is a PAID ADVERTISEMENT for Canary XRP ETF (NASDAQ:XRPC) from Market Jar Media Inc. StockEarnings, Inc. has received a fixed fee of $6000 from Market Jar Media Inc for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Nov 20, 2025 and Nov 26, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Canary XRP ETF (NASDAQ:XRPC) or Market Jar Media Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Canary XRP ETF (NASDAQ:XRPC) on TradingWhisperer website for additional information about the relationship between Market Jar Media Inc and Canary XRP ETF (NASDAQ:XRPC).

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com